In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Seres Therapeutics, Inc.

https://www.serestherapeutics.com/

Latest From Seres Therapeutics, Inc.

GvHD Could Yield To MaaT Pharma's Microbiome-Based Ecosystem Therapies

MaaT Pharma’s replacement bacterial ecosystem for the gastro-intestinal tract, MaaT103, has shown promise in top-line data from a Phase II study in patients with refractory aGvHD, energizing the microbiome field.

Clinical Trials Infectious Diseases

KoBioLabs Sees IPO Building Its Credentials As Global Microbiome Player

The Korean microbiome therapeutics developer KoBioLabs will launch a domestic IPO later this month and hopes to grow into a top three global company in the sector by 2025, helped by licensing deals.

South Korea Financing

Stockwatch: The Fall, Rise And Challenges Of Seres' Microbiome Therapy

The public biotech’s first foray into the microbiome started well, but a clinical trial failure followed by a success has now left Seres with both regulatory and commercial issues.

Companies Regulation

Early Success For 4D Pharma’s Microbiome Plus Keytruda Combination

After years of halting progress in its microbiome-based pipeline, 4D Pharma has produced promising early data from its cancer immunotherapy combination.

Clinical Trials Commercial
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Biotechnology
    • Drug Discovery Tools
    • Large Molecule
  • Other Names / Subsidiaries
    • Seres Health, Inc.
UsernamePublicRestriction

Register